Actinium Pharma Presents Survival Data From Extended Follow-Up From Actimab-A + CLAG-M Trial And Preclinical Data Supporting Program Expansion With FLT3 Inhibitor Combinations At SOHO
Portfolio Pulse from Happy Mohamed
Actinium Pharmaceuticals (ATNM) presented updated survival data from its Phase 1b trial evaluating Actimab-A in combination with the salvage chemotherapy CLAG-M in patients with high-risk relapsed or refractory acute myeloid leukemia (r/r AML). The trial showed a median overall survival of 24 months in all patients and 30 months in patients who received prior venetoclax treatment. The company also presented preclinical data supporting the clinical evaluation of Actimab-A combinations with FLT3 inhibitors.
September 07, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Actinium Pharmaceuticals' updated survival data from its Phase 1b trial and preclinical data supporting the clinical evaluation of Actimab-A combinations with FLT3 inhibitors could potentially boost investor confidence and positively impact the company's stock price.
The positive survival data from the Actimab-A + CLAG-M trial and the potential of Actimab-A combinations with FLT3 inhibitors could lead to increased investor confidence in Actinium Pharmaceuticals. This could result in increased demand for the company's stock, potentially driving up its price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100